Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...
Hosted on MSN
ADC Therapeutics (ADCT) upgraded to buy: Here's why
ADC Therapeutics SA (ADCT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results